In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Multimodality Management of Recurrent Skull Base Chordomas: Factors Impacting Tumor Control and Disease Specific Survival

    Final Number:
    1326

    Authors:
    Shaan Mohammed Raza MD; Diana MD Bell; Jacob Freeman MD; David Grosshans MD; Gregory N. Fuller MD, PhD; Franco DeMonte MD

    Study Design:
    Clinical Trial

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2017 Annual Meeting

    Introduction: Limited data exists to guide the management of recurrent skull base chordomas. There is a need to determine factors affecting outcomes in this high-risk population.

    Methods: A retrospective review was performed of 29 patients with 55 recurrences treated at our institution. Tumor and treatment factors were assessed for impact on median PFS (primary outcome) and DSS (secondary outcome). Fifty-five percent of the recurrences were after only surgical resection while 45% occurred after resection/adjuvant radiotherapy. Patterns of progression noted were local only (67%), distant only (15%), local + distant (18%).

    Results: Patients were less likely to respond to treatment once they reached their third recurrence (p<.05). Recurrence after radiation therapy trended towards worse outcomes in comparison to progression after surgery alone (15.9v41.4 months, p=.094). Distant disease spread and, specifically, LMD was associated with poorer DSS (p<.05) and PFS (p<.05). For local progression after surgery alone, repeat resection (p<.05) and radiation (p<.05) yielded improved tumor control rates. In the setting of local infield failure, repeat resection did not confer any benefit (13.5vs.17.6 months, p>.05) while a trend towards improved PFS was seen with SRS (28.3vs16.2 months, p=.233). For distant metastases, site directed therapy (surgery or radiation) allowed for site control (p<.05) but did not prevent overall disease progression. Progression within 6 months of primary therapy was also associated with a significant reduction in DSS (19.3vs.77.6 months, p<.05).

    Conclusions: There is a need for treatment of recurrent disease to be tailored to the pattern of recurrence and previously received treatments. The management of post-radiation progression poses particular challenges given the apparent limited role of repeat resection alone. SRS may have a role in this setting. While patients with systemic metastases appear to respond well to site directed therapy, those with LMD have a dismal prognosis. This study highlights areas of clinical management for future investigation.

    Patient Care: This research will help develop improved and systematic treatment strategies in the management of recurrent skull base chordomas.

    Learning Objectives: By the conclusion this session, participants should be able to: 1) Identify factors affecting local and distant tumor control rates in recurrent skull base chordoma. 2) Identify factors affecting survival in patients with recurrent skull base chordoma. 3)Identify the need for targeted treatment protocols in the management of recurrent skull base chordoma.

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy